Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IDYA NASDAQ:MRUS NASDAQ:RVMD NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIDYAIDEAYA Biosciences$26.92-2.1%$25.09$13.45▼$32.67$2.36B0.141.16 million shs682,357 shsMRUSMerus$94.39+0.1%$70.07$33.19▼$94.56$7.14B1.261.19 million shs2.70 million shsRVMDRevolution Medicines$46.570.0%$40.20$29.17▼$62.40$8.71B1.271.91 million shs900,663 shsVRNAVerona Pharma PLC American Depositary Share$106.95+0.1%$105.95$31.09▼$106.93$8.75B0.052.14 million shs1.87 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIDYAIDEAYA Biosciences-0.54%+1.10%+1.22%+28.16%-8.27%MRUSMerus-0.02%+0.64%+39.72%+80.15%+82.06%RVMDRevolution Medicines-0.28%+1.11%+15.01%+27.83%-1.56%VRNAVerona Pharma PLC American Depositary Share+0.11%+0.28%+0.56%+23.08%+233.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIDYAIDEAYA Biosciences$26.92-2.1%$25.09$13.45▼$32.67$2.36B0.141.16 million shs682,357 shsMRUSMerus$94.39+0.1%$70.07$33.19▼$94.56$7.14B1.261.19 million shs2.70 million shsRVMDRevolution Medicines$46.570.0%$40.20$29.17▼$62.40$8.71B1.271.91 million shs900,663 shsVRNAVerona Pharma PLC American Depositary Share$106.95+0.1%$105.95$31.09▼$106.93$8.75B0.052.14 million shs1.87 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIDYAIDEAYA Biosciences-0.54%+1.10%+1.22%+28.16%-8.27%MRUSMerus-0.02%+0.64%+39.72%+80.15%+82.06%RVMDRevolution Medicines-0.28%+1.11%+15.01%+27.83%-1.56%VRNAVerona Pharma PLC American Depositary Share+0.11%+0.28%+0.56%+23.08%+233.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIDYAIDEAYA Biosciences 2.72Moderate Buy$43.3661.06% UpsideMRUSMerus 2.16Hold$93.12-1.35% DownsideRVMDRevolution Medicines 2.93Moderate Buy$74.6460.28% UpsideVRNAVerona Pharma PLC American Depositary Share 2.07Hold$109.001.92% UpsideCurrent Analyst Ratings BreakdownLatest IDYA, VRNA, RVMD, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/6/2025MRUSMerusLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$95.00 ➝ $97.0010/5/2025MRUSMerusLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/30/2025MRUSMerusUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$72.00 ➝ $97.009/30/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Hold9/30/2025MRUSMerusBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$112.00 ➝ $97.009/30/2025MRUSMerusBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$112.00 ➝ $97.009/30/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$109.00 ➝ $97.009/30/2025MRUSMerusLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$97.009/29/2025MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$135.00 ➝ $97.009/29/2025MRUSMerusCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$67.00 ➝ $97.009/27/2025IDYAIDEAYA BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIDYAIDEAYA Biosciences$7M337.05N/AN/A$12.25 per share2.20MRUSMerus$56.23M126.97N/AN/A$9.46 per share9.98RVMDRevolution MedicinesN/AN/AN/AN/A$13.47 per shareN/AVRNAVerona Pharma PLC American Depositary Share$221.67M39.48N/AN/A$2.56 per share41.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIDYAIDEAYA Biosciences-$274.48M-$3.79N/AN/AN/AN/A-31.42%-29.45%11/3/2025 (Estimated)MRUSMerus-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.50N/AN/AN/AN/A-41.78%-35.63%11/5/2025 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$0.99N/A3,564.83N/A-36.62%-21.12%-9.07%11/3/2025 (Estimated)Latest IDYA, VRNA, RVMD, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/3/2025Q3 2025IDYAIDEAYA Biosciences-$0.12N/AN/AN/A$59.98 millionN/A11/3/2025Q3 2025VRNAVerona Pharma PLC American Depositary Share$0.17N/AN/AN/A$86.72 millionN/A10/30/2025Q3 2025MRUSMerus-$1.20N/AN/AN/A$8.73 millionN/A8/6/2025Q2 2025RVMDRevolution Medicines-$0.94-$1.31-$0.37-$1.31$0.50 millionN/A8/6/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share-$0.01$0.13+$0.14$0.13$90.41 million$103.14 million8/5/2025Q2 2025IDYAIDEAYA Biosciences-$0.85-$0.88-$0.03-$0.88$3.48 million$6.00 million8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIDYAIDEAYA BiosciencesN/A12.3912.39MRUSMerusN/A8.398.39RVMDRevolution Medicines0.1311.7911.79VRNAVerona Pharma PLC American Depositary Share0.8710.7110.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIDYAIDEAYA Biosciences98.29%MRUSMerus96.14%RVMDRevolution Medicines94.34%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipIDYAIDEAYA Biosciences2.50%MRUSMerus3.70%RVMDRevolution Medicines8.20%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIDYAIDEAYA Biosciences8087.64 million85.45 millionOptionableMRUSMerus3775.63 million72.84 millionOptionableRVMDRevolution Medicines250186.93 million171.60 millionOptionableVRNAVerona Pharma PLC American Depositary Share3081.83 million82.06 millionOptionableIDYA, VRNA, RVMD, and MRUS HeadlinesRecent News About These CompaniesVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Sets New 52-Week High - Still a Buy?October 7 at 7:36 AM | marketbeat.comBingham Private Wealth LLC Takes $240,000 Position in Verona Pharma PLC American Depositary Share $VRNAOctober 7 at 6:28 AM | marketbeat.comPlatinum Investment Management Ltd. Makes New Investment in Verona Pharma PLC American Depositary Share $VRNAOctober 2, 2025 | marketbeat.comAMI Asset Management Corp Sells 19,561 Shares of Verona Pharma PLC American Depositary Share $VRNAOctober 2, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 52-Week High - Here's WhyOctober 1, 2025 | marketbeat.comVerona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD PortfolioSeptember 30, 2025 | insidermonkey.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 1-Year High - Should You Buy?September 25, 2025 | marketbeat.comHere’s What Lifted Verona Pharma (VRNA) in Q2September 25, 2025 | insidermonkey.comShareholders of Verona Pharma Approve Proposed Acquisition by MerckSeptember 24, 2025 | globenewswire.comAtle Fund Management AB Raises Holdings in Verona Pharma PLC American Depositary Share $VRNASeptember 21, 2025 | marketbeat.comNorthCrest Asset Manangement LLC Decreases Stock Position in Verona Pharma PLC American Depositary Share $VRNASeptember 21, 2025 | marketbeat.comHarbor Capital Advisors Inc. Invests $1.49 Million in Verona Pharma PLC American Depositary Share $VRNASeptember 19, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given Consensus Rating of "Hold" by AnalystsSeptember 18, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 52-Week High - Here's What HappenedSeptember 17, 2025 | marketbeat.comVerona Pharma (VRNA) Rebounded from Challenging Q1September 16, 2025 | msn.comVerona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025September 16, 2025 | globenewswire.comVerona Pharma PLC American Depositary Share $VRNA Shares Purchased by Millennium Management LLCSeptember 15, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share $VRNA Shares Sold by Woodline Partners LPSeptember 13, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Sets New 12-Month High - Should You Buy?September 12, 2025 | marketbeat.comHere’s What Boosted Verona Pharma plc (VRNA) Share Price by 49%September 12, 2025 | insidermonkey.comFred Alger Management LLC Lowers Holdings in Verona Pharma PLC American Depositary Share $VRNASeptember 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIDYA, VRNA, RVMD, and MRUS Company DescriptionsIDEAYA Biosciences NASDAQ:IDYA$26.92 -0.57 (-2.07%) Closing price 04:00 PM EasternExtended Trading$26.93 +0.01 (+0.04%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Merus NASDAQ:MRUS$94.39 +0.12 (+0.13%) Closing price 04:00 PM EasternExtended Trading$94.49 +0.10 (+0.11%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Revolution Medicines NASDAQ:RVMD$46.57 -0.01 (-0.02%) Closing price 04:00 PM EasternExtended Trading$46.60 +0.02 (+0.05%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$106.94 +0.16 (+0.15%) Closing price 10/6/2025 07:05 PM EasternExtended Trading$106.94 0.00 (0.00%) As of 10/6/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Dividend Aristocrats to Buy Before Year’s End Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? TrumpRx Brings Pfizer Into the Green—Is It a Buy? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
